IV. 1 Tapering: gradually stepping down the dose

Tapering is a sign of recovery, not an increase in risk. In this chapter you will learn why and how your doctor steps your daily DiffBiome dose down in stages, what to watch for as you go, and how your diary decides whether you are ready for the next level.

What tapering is, and why it is not frightening

Picture it like timing when to take the cast off a broken arm. While the bone heals, the cast holds it in place; but if we left it on forever, the muscles would waste away, because they would get no work to do. The daily DiffBiome dose is a similar support: in the first weeks it delivers living gut flora frequently, so that it can engraft^[G] and push back Clostridioides difficile^[G]. Once that succeeds, the same frequent resupply is no longer needed – your own, strengthening microbiome^[G] begins to take over the work. Tapering is precisely what makes this possible: it gradually lets go of the support so that your own system can grow strong on its own.

That is why it is important to understand that tapering belongs in the good news category. The dose does not fall because something has "run out", or because you are getting less, but because your body no longer depends on the same amount. Many patients instinctively fear the reduction – "what if it comes back?" – yet tapering is exactly the phase in which we build the durability of recovery, not just momentary symptom relief.

What stepwise reduction looks like

Tapering does not happen overnight, straight down to zero, but in bands, in stages. Which day it starts on depends on how severe your starting point was: the more severe the start, the longer you stay on the full dose before we begin reducing. For those starting from the moderate classification, tapering typically begins after the fifth day; in the moderate-severe band, from day 7–8; in severe cases, after the tenth day. In other words, the greater the challenge was, the longer the period of "full protection" – and only afterwards do we begin to gently let go.

The reduction itself means that your daily capsule count is eased down step by step – for example from six to five, then to four – always waiting a few days at a given level. Each step poses one question: does the improvement hold even with a smaller dose? If it does, the next step can follow. If symptoms creep back, you and your doctor simply step back to the previous, safe level, and stay there longer. This is not a failure – it is the normal fine-tuning of tapering, and it works this way for everyone.

Your role in this is to keep the diary accurately, because the pace of tapering is told by the numbers, not by feeling. The daily stool count, the Bristol value^[G] and the trend in bloating together map out whether you are stable on the reduced dose. The decision is always made by your doctor – but you supply the evidence.

The protected window: what holds afterwards is decided now

There is an important truth around tapering that is easy to miss. The high-dose DiffBiome, together with engraftment, opened a protected window: the symptoms ease while the fresh flora is still only taking root. Until now, within this window the capsule provided most of the protection. With tapering, however, the protection gradually moves to where it durably belongs: to your own, strengthening microbiome and to your lifestyle. This is the turning point. As the dose falls, protection depends less and less on the capsule, and more and more on the habits you have built in.

That is why it matters what you laid down over the past weeks. What you built into the protected window – the varied, fibre-rich diet, the regular fluids, the sleep, the exercise, the stress relief – now really begins to work for you: it maintains colonisation resistance when the capsule support runs out. Tapering is therefore not only a question of dose, but also a call to action: the habits that are settling in now decide how resilient you will be once the capsule no longer protects you. The good news is that you have already begun these habits – the tapering period is precisely about letting them take the baton.

🍽️ Eating during these days

During the tapering days, eating mirrors the same shift as the dose: protection gradually moves from the capsule to your own, strengthening gut flora – and the chief food for this flora is plant fibre. So as the dose falls, the role of eating grows: the varied, fibre-rich plate is what maintains colonisation resistance when the capsule support runs out. The concrete eating task for the three days is simple: keep the familiar morning intake on an empty stomach with plenty of water, and every day work the day's plant into at least one meal, gently prepared. Keep an eye on fluid replacement during the taper too – an extra glass after every looser stool.

For these days (61–63), the Plant Calendar (Appendix F) brings three mushroom varieties: shiitake mushroom (61), button mushroom (62) and oyster mushroom (63). The beta-glucan^[G]-type soluble fibres of mushrooms provide well-fermentable food for the gut bacteria, which turn it into short-chain fatty acids^[G] – including butyrate^[G]; this butyrate is one of the main energy sources of the gut lining and a supporter of barrier integrity. In the second half of the programme (about days 61–90) this is exactly the goal: maintaining full plant diversity and fermentable fibre sources, because a diverse, well-fed flora is more resilient and leaves less room for the pathogen to return. If you do not tolerate one of the mushrooms well, leave it out and come back to it later.

Why does this matter?

Tapering is the phase in which recovery moves from a supported state to standing on its own feet. Stepwise reduction is not a risk, but a recognition of successful engraftment – and it happens gradually precisely so that, if something is not yet stable, you can step back in time and with ease. Here your diary is not paperwork, but the basis of the decision: the numbers tell us when the next step can come.

References

[7] van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013. Link

Open-label RCT in patients with recurrent C. difficile infection comparing duodenal donor faeces infusion (after short vancomycin + bowel lavage) with standard 14-day vancomycin, with or without bowel lavage. The primary endpoint was diarrhoea resolution without relapse at 10 weeks. The trial was stopped early at interim analysis: 13/16 patients (81\%) in the FMT arm achieved resolution after a single infusion, substantially exceeding both vancomycin arms. Establishes FMT as superior to antibiotic monotherapy for recurrent CDI and provides the landmark evidence base for FMT clinical translation.

[369] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome. 2015. Link

This study tracked fecal microbiota dynamics in four patients with multiply recurrent, antibiotic-refractory C. difficile infection treated with FMT, sampling daily up to 28 days and weekly up to 84 days post-FMT (with sampling out to 151 days). 16S rRNA gene profiling was compared to Human Microbiome Project body-site references. Pre-FMT samples were markedly dysbiotic. FMT produced a rapid normalization of fecal community composition toward a healthy donor-like state within days, and this normalization was largely sustained over months. Time-course visualization highlighted both rapid early shifts and longer-term stabilization. The findings document the kinetics of FMT-driven microbiota recovery in refractory CDI and support its durability.

[665] Seekatz A, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent. Therapeutic advances in gastroenterology. 2022. Link

Colonization resistance of the gut microbiota and FMT therapy in rCDI — A healthy microbiota inhibits C. difficile colonization (nutrient competition, bile acids, SCFAs, bacteriocins). Antibiotics → dysbiosis → CDI. FMT restores diversity. Monoclonal antibodies do not treat dysbiosis.

[667] Britton R, Young V. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014. Link

Intestinal microbiota and C. difficile colonization resistance — fundamental mechanisms — The native microbiota inhibits germination and growth of C. difficile spores. Antibiotics impair this defense. Key mechanisms: bile acid metabolism, nutrient competition. FMT restores colonization resistance.